Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Aripiprazole
Drug ID BADD_D00165
Description Aripiprazole is an atypical antipsychotic orally indicated for treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's[Label]. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania[Label]. Aripiprazole exerts its effects through agonism of dopaminic and 5-HT1A receptors and antagonism of alpha adrenergic and 5-HT2A receptors[Label,A4393]. Aripiprazole was given FDA approval on November 15, 2002[L6136].
Indications and Usage Aripiprazole is indicated for manic and mixed episodes associated with bipolar I disorder, irritability associated with autism spectrum disorder, treatment of schizophrenia, treatment of Tourette's disorder, and as an adjunctive treatment of major depressive disorder[Label]. An injectable formulation of aripiprazole is indicated for agitation associated with schizophrenia or bipolar mania[Label].
Marketing Status approved; investigational
ATC Code N05AX12
DrugBank ID DB01238
KEGG ID D01164
MeSH ID D000068180
PubChem ID 60795
TTD Drug ID D0H3HM
NDC Product Code 82009-090; 12658-0524; 46602-0009; 46602-0102; 46602-1030; 46602-1032; 49706-1889; 13668-219; 16729-279; 16729-280; 29300-176; 29300-179; 31722-820; 31722-829; 33342-126; 43547-302; 43598-969; 46708-260; 59148-031; 59148-033; 59148-114; 60505-2677; 60687-157; 65162-896; 65162-898; 67877-431; 68071-2705; 68382-083; 70518-3692; 71335-1515; 71335-1893; 72865-156; 76483-103; 82009-091; 0904-6512; 46602-1034; 53747-031; 65691-0052; 65841-140; 65862-680; 68554-0020; 13668-217; 27241-051; 31722-819; 31722-920; 31722-921; 43353-147; 43353-148; 43547-305; 48433-115; 48433-119; 50228-478; 59148-006; 59148-011; 59148-034; 59148-102; 60505-2674; 65162-899; 65862-664; 65862-666; 67877-435; 68382-439; 69452-339; 70518-2643; 70518-2736; 70518-2820; 70518-2869; 70771-1451; 72578-106; 76483-102; 0904-6656; 46602-0026; 65372-1121; 65862-661; 65862-663; 69037-0058; 27241-052; 27241-053; 27241-054; 31722-830; 33342-125; 48433-117; 50090-4800; 50268-091; 50268-092; 59148-009; 59148-019; 60687-168; 62332-097; 65162-893; 65162-897; 68788-7808; 70518-2515; 70518-2557; 70518-2825; 70518-2974; 70518-3090; 70771-1452; 71335-1832; 71428-018; 72189-476; 53808-1101; 59148-007; 59148-010; 59148-045; 60505-2673; 63739-074; 63739-078; 63739-413; 65162-902; 65862-662; 67877-434; 70518-2508; 70518-2584; 71205-392; 71335-1903; 72865-182; 72865-185; 76483-100; 0904-6511; 0904-6513; 46602-1029; 63415-0085; 13668-220; 16714-142; 16729-282; 16729-283; 43598-559; 43598-966; 46708-257; 46708-258; 50090-3941; 50090-4665; 50090-6563; 50228-326; 59148-008; 60505-2675; 60687-191; 60687-202; 60687-213; 62332-101; 63187-965; 63629-7774; 63739-069; 68382-084; 70518-2536; 70771-1454; 71205-480; 71335-1980; 72189-455; 72189-456; 72865-157; 72865-180; 82009-089; 12658-0602; 46602-1031; 50370-0009; 53104-7628; 13668-216; 16714-145; 29300-178; 43598-556; 43598-968; 46708-261; 50228-476; 50228-477; 50268-089; 50268-090; 59148-018; 59148-032; 60505-2676; 60505-3075; 62332-098; 62332-103; 65162-901; 67877-433; 70518-2827; 0615-8375; 72865-183; 76282-044; 76282-045; 76483-101; 12658-0599; 12828-0088; 46602-0006; 46602-0025; 58032-2005; 72761-020; 13668-221; 16714-143; 16729-278; 16729-281; 27241-055; 31722-919; 31722-922; 31722-924; 43598-557; 46708-259; 48433-120; 59148-029; 59651-110; 62332-102; 68382-085; 68788-7006; 68788-7063; 68788-7733; 68788-7749; 68788-8089; 70518-0970; 70518-2580; 70518-2958; 70771-1455; 72865-153; 72865-155; 72865-181; 82009-088; 0904-6510; 12658-0577; 46602-1033; 50370-0044; 50370-0055; 29300-175; 29300-180; 43547-303; 43547-304; 43598-554; 43598-965; 43598-970; 46708-255; 50090-6063; 50228-325; 50228-475; 60505-0404; 65862-665; 69452-338; 70518-2567; 70771-1453; 70771-1456; 71335-1513; 72865-184; 76282-048; 0904-6514; 12658-0542; 46602-0010; 46602-0072; 58623-0127; 65096-0107; 16714-146; 33342-122; 33342-127; 43353-140; 43547-306; 43598-967; 46708-256; 48433-116; 50090-6403; 60687-179; 62332-099; 63739-070; 66689-735; 67877-430; 67877-432; 68382-086; 70518-1295; 70518-2806; 70518-2950; 71335-1682; 71335-1892; 72578-107; 72865-154; 72888-100; 76282-047; 76282-049; 46602-0007; 46602-0008; 46602-0045; 46602-0114; 59116-2900; 59116-2901; 67835-0009; 68554-0095; 76072-1002; 13668-218; 29300-177; 31722-828; 33342-123; 33342-124; 43547-307; 46708-254; 50228-329; 50268-088; 54838-570; 62332-100; 62332-104; 63629-7108; 68071-2676; 68071-2708; 68382-082; 70518-2765; 70518-2897; 70518-2921; 70518-3380; 71335-1687; 71335-1935; 72189-466; 72865-158; 76282-046; 0904-6509; 12658-0576; 12658-0601; 14445-019; 46602-0011; 64220-112; 16714-141; 16714-144; 16714-785; 27241-056; 31722-827; 31722-923; 43353-180; 43598-555; 43598-558; 48433-118; 50090-5839; 50090-6409; 50228-324; 50228-327; 50228-328; 50228-479; 50228-480; 50268-087; 59148-030; 59148-072
UNII 82VFR53I78
Synonyms Aripiprazole | 7-(4-(4-(2,3-dichlorophenyl)-1-piperazinyl)butyloxy)-3,4-dihydro-2(1H)-quinolinone | Aripiprazol | Abilify | OPC 14597 | OPC-14597
Chemical Information
Molecular Formula C23H27Cl2N3O2
CAS Registry Number 129722-12-9
SMILES C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Vertigo04.04.01.003; 17.02.12.0020.001577%
Vertigo positional17.02.12.004; 04.04.01.005--Not Available
Vision blurred17.17.01.010; 06.02.06.007--
Visual acuity reduced06.02.10.012; 17.17.01.0110.000666%
Visual impairment06.02.10.013--Not Available
Vitamin B12 deficiency14.12.02.0040.000119%Not Available
Vitreous detachment12.01.04.005; 06.09.01.0020.000079%Not Available
Vomiting07.01.07.003--
Vulvovaginal candidiasis21.14.02.003; 11.03.03.005--Not Available
Vulvovaginal dryness21.08.02.003--
Weight decreased13.15.01.005--
Weight gain poor14.03.02.0180.000079%Not Available
Weight increased13.15.01.006--
Wheezing22.03.01.009--
White blood cell count decreased13.01.06.012--
White blood cell count increased13.01.06.013--Not Available
White blood cells urine positive13.13.02.004--Not Available
Withdrawal syndrome19.07.06.023; 08.06.02.0120.001252%Not Available
Xerophthalmia14.12.03.002; 06.06.03.0080.000119%Not Available
Xerosis08.01.03.016--Not Available
Mental status changes19.07.01.0010.001197%Not Available
Mobility decreased15.03.05.023; 17.02.05.018; 08.01.03.030--Not Available
Fibromyalgia15.05.02.0020.000119%Not Available
Lip disorder07.05.01.0080.000174%Not Available
Post thrombotic syndrome24.01.01.0190.000119%Not Available
Joint range of motion decreased15.01.02.006--
Urosepsis20.08.02.002; 11.01.11.005--Not Available
Energy increased08.01.03.0170.000428%Not Available
Hypoacusis04.02.01.006--
Paradoxical drug reaction08.06.01.0140.000174%Not Available
The 28th Page    First    Pre   28 29 30 31 32    Next   Last    Total 40 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene